Literature DB >> 15099183

Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles.

Paul M Bummer1.   

Abstract

Of all the methods employed by formulators when presented with the task of improving oral bioavailability, the use of lipid assemblies is perhaps the least understood. Nonetheless, lipid-based formulations, and in particular solid lipid nanoparticles (SLN), show great promise for enhancing the oral bioavailability of some of the most poorly absorbed compounds. The physical/chemical characteristics of lipid-based systems are highly complex because of the existence of a variety of lipid assembly morphologies, the morphology-dependent solubility of drug, the interconversion of assembly morphology as a function of time and chemical structure, and the simultaneous lipid digestion. The present work will center on recent studies of the relevant physicochemical characteristics of SLN, most notably solubility of the drug in the lipid matrix, location of the drug in the aggregate, drug release properties of the aggregate, and particle size stability. Strengths and weaknesses of the lipid assemblies, in particular solid lipid nanoparticles, in promoting drug delivery by the oral route for systemic or Peyer's patch uptake will be highlighted, and possible future research pathways will be suggested. Copyright 2004 Begell House, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099183

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  19 in total

Review 1.  Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis.

Authors:  Jonathan Paul Smith
Journal:  Yale J Biol Med       Date:  2011-12

Review 2.  The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.

Authors:  Svetlana Gelperina; Kevin Kisich; Michael D Iseman; Leonid Heifets
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

Review 3.  Recent trends on hydrogel based drug delivery systems for infectious diseases.

Authors:  Arti Vashist; Ajeet Kaushik; Atul Vashist; Rahul Dev Jayant; Asahi Tomitaka; Sharif Ahmad; Y K Gupta; Madhavan Nair
Journal:  Biomater Sci       Date:  2016-10-18       Impact factor: 6.843

4.  Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN).

Authors:  Yongqiang Li; Nicolas Taulier; Andrew M Rauth; Xiao Yu Wu
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

5.  Design expert assisted formulation, characterization and optimization of microemulsion based solid lipid nanoparticles of repaglinide.

Authors:  Balaji Maddiboyina; Vikas Jhawat; Ramya Krishna Nakkala; Prasanna Kumar Desu; Sivaraman Gandhi
Journal:  Prog Biomater       Date:  2021-11-23

Review 6.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

7.  A novel nanoparticle formulation for sustained paclitaxel delivery.

Authors:  W J Trickler; A A Nagvekar; A K Dash
Journal:  AAPS PharmSciTech       Date:  2008-03-18       Impact factor: 3.246

8.  Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus Calmette-Guerin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis.

Authors:  Simon Clark; Martin L Cross; Allan Nadian; Julia Vipond; Pinar Court; Ann Williams; R Glyn Hewinson; Frank E Aldwell; Mark A Chambers
Journal:  Infect Immun       Date:  2008-06-02       Impact factor: 3.441

9.  Nanoparticle-based targeted gene therapy for lung cancer.

Authors:  Hung-Yen Lee; Kamal A Mohammed; Najmunnisa Nasreen
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

10.  Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization.

Authors:  Xiaowei Dong; Cynthia A Mattingly; Michael Tseng; Moo Cho; Val R Adams; Russell J Mumper
Journal:  Eur J Pharm Biopharm       Date:  2008-12-10       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.